JP2022513311A - カーゴ積載細胞外小胞 - Google Patents

カーゴ積載細胞外小胞 Download PDF

Info

Publication number
JP2022513311A
JP2022513311A JP2021541011A JP2021541011A JP2022513311A JP 2022513311 A JP2022513311 A JP 2022513311A JP 2021541011 A JP2021541011 A JP 2021541011A JP 2021541011 A JP2021541011 A JP 2021541011A JP 2022513311 A JP2022513311 A JP 2022513311A
Authority
JP
Japan
Prior art keywords
cells
rbcev
aso
extracellular vesicles
cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541011A
Other languages
English (en)
Japanese (ja)
Inventor
シー,ジアハイ
ル,ティ・グエット・ミン
ワカス,ムハンマド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City University of Hong Kong
Original Assignee
City University of Hong Kong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City University of Hong Kong filed Critical City University of Hong Kong
Publication of JP2022513311A publication Critical patent/JP2022513311A/ja
Priority to JP2023073005A priority Critical patent/JP2023099092A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021541011A 2018-09-21 2018-12-06 カーゴ積載細胞外小胞 Pending JP2022513311A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023073005A JP2023099092A (ja) 2018-09-21 2023-04-27 カーゴ積載細胞外小胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734303P 2018-09-21 2018-09-21
US62/734,303 2018-09-21
PCT/SG2018/050596 WO2020060479A1 (en) 2018-09-21 2018-12-06 Cargo loaded extracellular vesicles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023073005A Division JP2023099092A (ja) 2018-09-21 2023-04-27 カーゴ積載細胞外小胞

Publications (1)

Publication Number Publication Date
JP2022513311A true JP2022513311A (ja) 2022-02-07

Family

ID=69887709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541011A Pending JP2022513311A (ja) 2018-09-21 2018-12-06 カーゴ積載細胞外小胞
JP2023073005A Pending JP2023099092A (ja) 2018-09-21 2023-04-27 カーゴ積載細胞外小胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023073005A Pending JP2023099092A (ja) 2018-09-21 2023-04-27 カーゴ積載細胞外小胞

Country Status (3)

Country Link
US (1) US20210355492A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022513311A (cg-RX-API-DMAC10.html)
WO (1) WO2020060479A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021145821A1 (en) 2020-01-13 2021-07-22 Carmine Therapeutics Pte. Ltd. Nucleic acid loaded red blood cell extracellular vesicles
WO2021212066A2 (en) * 2020-04-17 2021-10-21 Ohio State Innovation Foundation Rbc extracellular vesicles
CN117202894A (zh) * 2021-03-31 2023-12-08 胭脂红治疗私人有限公司 负载至少两个不同核酸的细胞外囊泡
IT202100027725A1 (it) * 2021-10-28 2023-04-28 Torino Politecnico Metodo per l’ottenimento di popolazioni concentrate di vescicole extracellulari lavate del loro carico fisio-patologico
JP2024540165A (ja) * 2021-11-01 2024-10-31 シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Crispr-casシステムのためのエレクトロポレーションエンハンサー
CN116763817A (zh) * 2022-03-08 2023-09-19 中山大学 血液来源的样品在制备囊泡中的应用
WO2023172208A1 (en) * 2022-03-11 2023-09-14 National University Of Singapore Vesicle-based compositions and uses thereof
CN117126888A (zh) * 2023-06-21 2023-11-28 安徽省立医院(中国科学技术大学附属第一医院) 装载蛋白或多肽的细胞外囊泡递送平台及其应用
IT202300026244A1 (it) * 2023-12-07 2025-06-07 Univerista Degli Studi Di Urbino Carlo Bo Vescicole extracellulari derivate da globuli rossi caricate con molecole di carico per applicazioni terapeutiche e metodo di produzione delle stesse

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274630A1 (en) * 2008-05-01 2009-11-05 National Health Research Institutes Red blood cell-derived vesicles as a nanoparticle drug delivery system
JP2013515495A (ja) * 2009-12-28 2013-05-09 セントレ デ レセルカ エン サルト インテルナシオナル デ バルセロナ プラスモジウム種に感染した網状赤血球由来のエキソソーム、それらの取得方法およびその用途
WO2016187717A1 (en) * 2015-05-26 2016-12-01 Exerkine Corporation Exosomes useful for genome editing
JP2017504312A (ja) * 2013-12-12 2017-02-09 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのCRISPR−Cas系及び組成物の送達、使用及び治療適用
US20180067134A1 (en) * 2016-09-08 2018-03-08 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing parkinson's disease
US20180161416A1 (en) * 2015-06-03 2018-06-14 Innovex Therapeutics, S.L. Exosomes and their use as vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017335084B2 (en) * 2016-09-30 2023-06-29 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274630A1 (en) * 2008-05-01 2009-11-05 National Health Research Institutes Red blood cell-derived vesicles as a nanoparticle drug delivery system
JP2013515495A (ja) * 2009-12-28 2013-05-09 セントレ デ レセルカ エン サルト インテルナシオナル デ バルセロナ プラスモジウム種に感染した網状赤血球由来のエキソソーム、それらの取得方法およびその用途
JP2017504312A (ja) * 2013-12-12 2017-02-09 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのCRISPR−Cas系及び組成物の送達、使用及び治療適用
WO2016187717A1 (en) * 2015-05-26 2016-12-01 Exerkine Corporation Exosomes useful for genome editing
US20180161416A1 (en) * 2015-06-03 2018-06-14 Innovex Therapeutics, S.L. Exosomes and their use as vaccine
US20180067134A1 (en) * 2016-09-08 2018-03-08 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing parkinson's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANESH A, ET AL.: "Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting", BLOOD, vol. 123(5), JPN6022045337, 30 January 2014 (2014-01-30), pages 687 - 696, ISSN: 0005121105 *
GANGADARAN P, ET AL.: "In vivo Non-invasive Imaging of Radio-Labeled Exosome-Mimetics Derived From Red Blood Cells in Mice", FRONT PHARMACOL, vol. 9, JPN6022045338, 30 July 2018 (2018-07-30), pages 817, ISSN: 0004907740 *
PRUDENT M, ET AL.: "Differences between calcium-stimulated and storage-induced erythrocyte-derived microvesicles", TRANSFUS APHER SCI, vol. 53(2), JPN6022045336, October 2015 (2015-10-01), pages 153 - 158, ISSN: 0005295584 *

Also Published As

Publication number Publication date
WO2020060479A1 (en) 2020-03-26
JP2023099092A (ja) 2023-07-11
US20210355492A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
JP2023099092A (ja) カーゴ積載細胞外小胞
JP7343920B2 (ja) マトリックス結合ナノベシクルおよびその使用
Usman et al. Efficient RNA drug delivery using red blood cell extracellular vesicles
US10709797B2 (en) Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
EP3563859B1 (en) Cardiosphere-derived exosomes for tissue regeneration
US11970718B2 (en) Nucleic acid loaded extracellular vesicles
AU2019243179B2 (en) Use of exosomes for targeted delivery of therapeutic agents
JP7602246B2 (ja) エキソソームを用いる腫瘍抑制因子の治療的調整法
CN108175759A (zh) 一种抗肿瘤靶向给药系统及其制备方法与应用
US20210369858A1 (en) Use of exosomes for targeted delivery of therapeutic agents
JP7599698B2 (ja) エキソソームを用いたがん遺伝子に対する治療的な標的指向化の方法
Tan et al. Skimmed bovine milk-derived extracellular vesicles isolated via “salting-out”: Characterizations and potential functions as nanocarriers
WO2016196822A1 (en) Urodele exosomes as therapeutic agents
US20260102512A1 (en) Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia
CN108175861A (zh) 一种抗肿瘤小核酸药物的递送系统及其应用
WO2024196875A1 (en) Compositions and methods useful for the treatment and management of obesity associated metabolic dysfunction
AU2022386233A1 (en) Biomarkers of megakaryocyte-derived extracellular vesicles
CN117580949A (zh) 工程化的胞外囊泡
Pottash Strategies for small RNA loading into extracellular vesicles
Phan Cardioprotective Extracellular Vesicles Derived-Micrornas: Sorting Mechanisms and Functions
HK40006800A (en) Isolation of extracellular vesicles from red blood cells for gene therapy
HK1260123A1 (en) Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210519

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402